The market is driven by the increasing prevalence of obesity and type 2 diabetes throughout the world, the effectiveness of GLP-1 agonists in terms of significant weight loss and glucose management, and active consumer promotion campaigns and reimbursement coverage
Both have received FDA inspection findings
Whether your experience was excellent, average, or disappointing, we want to hear from you
When discussing Semaglutide, most of us think of its game-changing effects on weight loss and diabetes management
Importantly, systemic semaglutide activates LC-NE neurons, and its acute appetite-suppressing effects are blunted when GLP-1Rs in the LC are blocked with local infusion of exendin-9 [91]
Injection-day avoidance remains relevant